(Press-News.org) Australian media release (see below for North American media release)
A landmark Lancet Psychiatry paper published today – the largest-ever review of the safety and efficacy of cannabinoids across a range of mental health conditions – found no evidence that medicinal cannabis is effective in treating anxiety, depression or post-traumatic stress disorder (PTSD).
The study comes amid more than one million prescription approvals and a tripling of sales of cannabinoid medications (including both cannabidiol (CBD) and tetrahydrocannabinol (THC) products) in Australia over the past four years, often for the treatment of mental health and substance-use disorders.
The study’s lead author, Dr Jack Wilson at the University of Sydney’s The Matilda Centre, said the results call into question the approval of medicinal cannabis for the treatment of depression, anxiety and PTSD.
“Though our paper didn’t specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments,” he said.
More than 700,000 Australians have reported using medicinal cannabis to treat over 250 different health conditions. The research found evidence to suggest that medicinal cannabis could potentially be beneficial for some conditions – such as the treatment of cannabis use disorder (otherwise known as cannabis dependency), autism, insomnia, and tics or Tourette’s syndrome.
Dr Wilson said: “But the overall quality of evidence for these other conditions, such as autism and insomnia, was low. In the absence of robust medical or counselling support, the use of medicinal cannabis in these cases are rarely justified.
“There is, however, evidence that medicinal cannabis may be beneficial in certain health conditions, such as reducing seizures associated with some forms of epilepsy, spasticity among those with multiple sclerosis, and managing certain types of pain, but our study shows the evidence for mental health disorders falls short.
“In the case of autism specifically, while the study showed some evidence medicinal cannabis could assist with a reduction in symptoms, it is worth noting that there is no one – or universal – experience of autism, so this finding should be treated with caution.”
The study found that medicinal cannabis was not effective for every type of substance-abuse disorder. While medicinal cannabis may help with cannabis dependence, it was found to increase cocaine cravings among people with cocaine-use disorder
“Similar to how methadone is used to treat opioid-use disorder, cannabis medicines may form part of an effective treatment for those with a cannabis-use disorder. When administered alongside psychological therapy, an oral formulation of cannabis was shown to reduce cannabis smoking,” Dr Wilson said.
“However, when medicinal cannabis was used to treat people with cocaine-use disorder, it increased their cravings. This means it should not be considered for this purpose and may, in fact, worsen cocaine dependence,” he said.
Researchers urge greater regulation for prescribing of medicinal cannabis
The rapid expansion in medicinal cannabis use and prescribing rates has raised concerns among major medical bodies, including the Australian Medical Association (AMA) and the Pharmacy Guild of Australia, about the largely unregulated growth in prescribing and the uncertainty surrounding the efficacy and safety of these products.
In response, the Therapeutic Goods Administration (TGA) initiated a review of the regulatory oversight of medicinal cannabis, with more than 500 responses published in February.
“Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support the TGA and clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimising harm from ineffective or unsafe cannabis products,” Dr Wilson said.
The systematic review and meta-analysis included results from 54 randomised controlled trials (RCTs) published over a 45-year period (1980-2025) worldwide.
Interviews: Dr Jack Wilson is available for interview, please contact Luisa Low.
Research: Wilson, J et al, ‘The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis' (The Lancet Psychiatry, 2026)
DOI: https://doi.org/10.1016/S2215-0366(26)00015-5
North American media release
No evidence to suggest medicinal cannabis is effective for depression, anxiety or PTSD: research
A landmark Lancet paper published today – the largest-ever review of the safety and efficacy of cannabinoids across a range of mental health conditions – found no evidence that medicinal cannabis is effective in treating anxiety, depression or post-traumatic stress disorder (PTSD).
The study comes amid findings that 27 percent of people aged 16–65 in the United States and Canada have used cannabis for medical purposes, with about half using it to manage their mental health.
The study’s lead author, Dr Jack Wilson at the University of Sydney’s The Matilda Centre, said the results call into question the approval of medicinal cannabis for the treatment of depression, anxiety and PTSD.
“Though our paper didn’t specifically look at this, the routine use of medicinal cannabis could be doing more harm than good by worsening mental health outcomes, for example a greater risk of psychotic symptoms and developing cannabis use disorder, and delaying the use of more effective treatments,” he said.
The research found evidence to suggest that medicinal cannabis could potentially be beneficial for some conditions – such as the treatment of cannabis use disorder (otherwise known as cannabis dependency), autism, insomnia, and tics or Tourette’s syndrome.
Dr Wilson said: “But the overall quality of evidence for these other conditions, such as autism and insomnia, was low. In the absence of robust medical or counselling support, the use of medicinal cannabis in these cases are rarely justified.
“There is, however, evidence that medicinal cannabis may be beneficial in certain health conditions, such as reducing seizures associated with some forms of epilepsy, spasticity among those with multiple sclerosis, and managing certain types of pain, but our study shows the evidence for mental health disorders falls short.
“In the case of autism specifically, while the study showed some evidence medicinal cannabis could assist with a reduction in symptoms, it is worth noting that there is no one – or universal – experience of autism, so this finding should be treated with caution.”
The study found that medicinal cannabis was not effective for every type of substance-abuse disorder. While medicinal cannabis may help with cannabis dependence, it was found to increase cocaine cravings among people with cocaine-use disorder
“Similar to how methadone is used to treat opioid-use disorder, cannabis medicines may form part of an effective treatment for those with a cannabis-use disorder. When administered alongside psychological therapy, an oral formulation of cannabis was shown to reduce cannabis smoking,” Dr Wilson said.
“However, when medicinal cannabis was used to treat people with cocaine-use disorder, it increased their cravings. This means it should not be considered for this purpose and may, in fact, worsen cocaine dependence,” he said.
Researchers urge greater regulation for prescribing of medicinal cannabis
The rapid expansion in medicinal cannabis use and prescribing rates has raised concerns among major medical bodies, including the American Medical Association about the largely unregulated growth in prescribing and the uncertainty surrounding the efficacy and safety of these products.
“Our study provides a comprehensive and independent assessment of the benefits and risks of cannabis medicines, which may support clinicians to make evidence-based decisions, helping to ensure patients receive effective treatments while minimising harm from ineffective or unsafe cannabis products,” Dr Wilson said.
The systematic review and meta-analysis included results from 54 randomised controlled trials (RCTs) published over a 45 year period (1980-2025) worldwide.
Interviews:
Dr Jack Wilson is available for interview, please contact Luisa Low.
Research: Wilson, J et al, ‘The efficacy and safety of cannabinoids for the treatment of mental disorders and substance use disorders: a systematic review and meta-analysis' (The Lancet Psychiatry, 2026)
DOI: https://doi.org/10.1016/S2215-0366(26)00015-5
Declaration:
The research was funded by the NHMRC. Wayne Hall and Myfanwy Graham have received consultation fees from the World Health Organization. Wayne Hall has received payment for expert testimony on the risks of cannabis use. Myfanwy Graham is an appropriate member of the Medicinal Cannabis Expert Working Group, Australian Department of Health, Ageing and Disability. Myfanwy Graham has also received funding from the Therapeutic Goods Administration for independent evidence reviews on medicinal cannabis. All other authors declare no competing interests.
Media enquiries:
Luisa Low, Senior Media and PR Adviser | Luisa.low@sydney.edu.au | +61 438 021 390
Outside of work hours: please call +61 2 8627 0246 (directs to a mobile number) or email media.office@sydney.edu.au
END
No evidence to suggest medicinal cannabis is effective for depression, anxiety or PTSD: research
2026-03-17
ELSE PRESS RELEASES FROM THIS DATE:
The Lancet Global Health: Modelling suggests climate change could drive millions globally into physical inactivity by 2050 and be linked to an estimated half a million premature deaths
2026-03-17
The Lancet Global Health: Modelling suggests climate change could drive millions globally into physical inactivity by 2050 and be linked to an estimated half a million premature deaths
Rising temperatures due to climate change could drive millions more adults globally into physical inactivity by 2050, being linked to hundreds of thousands of premature deaths and billions of dollars in lost productivity, suggests a modelling study published in The Lancet Global Health journal.
Climate change is making the world hotter, and this growing heat is likely to affect how active people can be. Physical inactivity is already a major global health problem, ...
Fathers’ health crucial to improving pregnancy and child outcomes
2026-03-17
UNDER EMBARGO UNTIL 23:30 UK TIME ON MONDAY 16 MARCH 2026
Fathers’ health crucial to improving pregnancy and child outcomes
Researchers say boys and men are an important but ‘persistently under-appreciated’ population for measures to improve the health of the next generation of children
Improving health and well-being of future fathers critical to addressing intergenerational disparities and legacies of racism
A focus on shared responsibility for pregnancy and parenthood ...
Major step towards a first global system to track health before pregnancy
2026-03-17
Under embargo to Monday 16 March 2026, 23:30 UK time
Peer reviewed / Survey
Major step towards a first global system to track health before pregnancy
The key health and social indicators needed for a new global system to monitor people’s health before pregnancy have been identified for the first time by researchers at University College London and the University of Southampton.
As more women are becoming pregnant with health conditions that can complicate pregnancy and childbirth, such as obesity, diabetes ...
Climate action could prevent over 13 million premature deaths, but equity choices matter for global health
2026-03-16
A new study published in The Lancet Global Health reveals a previously underappreciated tension at the heart of international climate negotiations: policies designed to protect developing countries from bearing an unfair share of the cost of cutting carbon emissions could inadvertently deprive those same countries of millions of life-saving air quality improvements. The leaders of the study also identify a promising way to resolve this dilemma.
The study, conducted by researchers at The University of Texas at Austin, Emory University, Princeton University, and collaborators across six countries, modeled ...
Bull sharks have ‘friends’
2026-03-16
Bull sharks form social relationships with specific “friends”, new research reveals.
Sharks are often viewed as solitary, but the study – carried out on the Shark Reef Marine Reserve in Fiji – found that rather than mixing at random, sharks have “active social preferences” and choose their social partners.
The research was carried out by the University of Exeter, University of Lancaster, Fiji Shark Lab, and Beqa Adventure Divers.
“As humans we cultivate a range of social relationships – from casual acquaintances to our best friends, but we also actively avoid certain ...
New research shows how to diagnose people with Alzheimer’s plus a hard-to-identify dementia type
2026-03-16
PROVIDENCE, R.I. [Brown University] — People with Alzheimer’s disease often have other neurodegenerative conditions as well, including a less-understood disorder called frontotemporal lobar degeneration (FTLD). While a precise diagnosis of FTLD has only been possible during an autopsy, new research shows how clinicians may be able to diagnose people living with both Alzheimer’s and FTLD by evaluating neuropsychiatric symptoms.
In a study published in Neurology, researchers found that compared to patients who have either of the two types of dementia alone, having both Alzheimer’s disease and FTLD is associated with greater likelihood of having known neuropsychiatric symptoms ...
Large craters offer clues to the origin of asteroid 16 Psyche
2026-03-16
Even 200 years after asteroid 16 Psyche was discovered, astronomers continue to puzzle over its formation.
Psyche is the 10th-most massive asteroid in the main belt between Mars and Jupiter, and the largest known metallic asteroid, at 140 miles in diameter. NASA's Psyche mission will arrive in 2029 to determine its origin. Psyche may be a leftover building block of an early planet, shredded by violent collisions, or a planetary fragment that once separated into layers before losing its rocky outer mantle.
Other hypotheses suggest Psyche is an ancient remnant that either started metal-rich ...
Researchers develop biochar-based photocatalyst that rapidly removes antibiotic pollutants from water
2026-03-16
A new study reports that a biochar-enhanced photocatalyst can efficiently degrade antibiotic contaminants in water, offering a promising strategy for addressing one of the growing threats to global water quality.
The research, published in the journal Biochar, describes the development of a ternary composite material composed of biochar, titanium dioxide, and graphitic carbon nitride. The material demonstrated remarkable ability to break down sulfadiazine, a widely used sulfonamide antibiotic that is frequently detected in aquatic environments.
Antibiotic pollution has become ...
ACP supports AAP’s evidence‑based childhood vaccine schedule
2026-03-16
Embargoed for release until 5:00 p.m. ET on Monday 16 March 2026
Follow @Annalsofim on X, Facebook, Instagram, Bluesky, and LinkedIn
Below please find summaries of new articles that will be published in the next issue of Annals of Internal Medicine. The summaries are not intended to substitute for the full articles as a source of information. This information is under strict embargo and by taking it into possession, media representatives are committing to the terms of the embargo not only on their own ...
Half of Native Hawaiian University of Hawaiʻi students experience period poverty, study reveals
2026-03-16
Approximately 14% of college students across the United States experience period poverty – meaning they cannot afford to purchase or access menstrual products. A new study of 462 college students in the University of Hawai’i school system reveals that period poverty may be notably higher for this population.
Period poverty can be a heavy burden for college students. Prior research links insufficient access to safe hygiene products (ex., tampons, sanitary napkins, pads, menstrual cups) with mental health challenges, increased risk of urogenital infections ...